Anglia Ruskin University research finds GLP-1 drugs cut cardiovascular risk by 13%
Updated
Updated · SciTechDaily · May 2
Anglia Ruskin University research finds GLP-1 drugs cut cardiovascular risk by 13%
9 articles · Updated · SciTechDaily · May 2
The meta-analysis reviewed 11 trials covering more than 90,000 patients and found benefits over nearly three years, including lower risks of heart attack, stroke and cardiovascular death.
Researchers said the effect appeared regardless of diabetes status, with fewer nonfatal heart attacks, nonfatal strokes, heart failure hospitalisations and deaths from any cause versus placebo.
Benefits were strongest in high-risk groups such as people with type 2 diabetes, obesity or existing heart disease, while serious safety issues were not meaningfully increased, though nausea and vomiting were more common.
Are we trading future heart attacks for brittle bones with long-term use of weight-loss drugs?
If stopping GLP-1 drugs erases their benefits, is lifelong dependency the only path to better health?
The Critical Role of Adherence: How Stopping GLP-1RAs Reverses a 13.45% Cardiovascular Risk Reduction in Type 2 Diabetes
Overview
Recent research confirms that continuous use of GLP-1 receptor agonists (GLP-1RAs) significantly reduces cardiovascular risk in people with type 2 diabetes and obesity, lowering major adverse cardiovascular events by up to 18%. However, stopping or interrupting treatment causes a rapid reversal of benefits—known as metabolic whiplash—leading to weight regain, worsened blood sugar, blood pressure, and cholesterol, which increases cardiovascular risk by 22% after two years off therapy. Combining GLP-1RA treatment with healthy lifestyle habits further amplifies protection, reducing cardiovascular events by 43%. Despite these benefits, high discontinuation rates driven by side effects and cost barriers threaten long-term success, highlighting the urgent need for strategies to support adherence and continuous therapy.